Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements
Manuela Braun(Bayer (Germany)), Mark Milton(Novartis (United States)), Vibha Jawa(EpiVax (United States)), Daisy Yuill(The Francis Crick Institute), Louis Christodoulou(UCB Pharma (United Kingdom)), Nicole L. Miller(Vanderbilt University Medical Center), Tong‐Yuan Yang(Johnson & Johnson (United States)), Boris Gorovits(Pfizer (United States)), Edit Tarcsa(Massachusetts Academy of Math and Science at WPI), Fraser McBlane(Novartis (Switzerland)), Claudia Lange(Bayer (Germany)), Philipp Schatz(AstraZeneca (Sweden)), Wibke Lembke, Brian Long(BioMarin (United States)), Johannes Stanta
Cited by 25
Related Papers
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
|Journal of Clinical Oncology|2020|73